RecruitingNot ApplicableNCT03987308

Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Treatment of Patients With Newly Diagnosed Type 2 Diabetes: a Multicenter, Randomized Open Trial Study With Parallel Controls

Sponsor

Beijing Hospital

Enrollment

115 participants

Start Date

Jul 2, 2019

Study Type

INTERVENTIONAL

Conditions

T2DM T2DM (Type 2 Diabetes Mellitus)Type 2 Diabetic Patients

Summary

The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study compares two treatments for newly diagnosed type 2 diabetes in people with high blood sugar: continuous under-the-skin injections of beinaglutide (a GLP-1 receptor agonist similar to semaglutide) versus continuous insulin infusion via pump. The goal is to see which approach controls blood sugar more effectively early on. **You may be eligible if...** - You are 18 to 70 years old - You have been newly diagnosed with type 2 diabetes (within the past year) - Your HbA1c (3-month blood sugar average) is between 7.5% and 10% - Your BMI is between 24 and 42 kg/m² - You have not been on diabetes medication, or have only been on oral drugs for less than 3 months (and stopped at least 1 month ago) **You may NOT be eligible if...** - You have type 1 diabetes or have had diabetes for more than 1 year - Your HbA1c or BMI is outside the eligible range - You are pregnant or not using effective contraception Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBeinaglutide

Beinaglutide (continuous subcutaneous infusion)

DRUGInsulin aspart

Insulin aspart (CSII)

Locations(16)

Pinggu District Hospital

Beijing, Beijing Municipality, China

Capital Medical University Beijing Anzhen Hospital

Beijing, Beijing Municipality, China

Emergency General Hospital

Beijing, Beijing Municipality, China

Peking University Shougang Hospital

Beijing, Beijing Municipality, China

Southern Medical University Nanfang Hospital

Guangzhou, Guangdong, China

Harbin Medical University Second Hospital

Harbin, Heilongjiang, China

Southeast University Zhongda Hospital

Nanjing, Jiangsu, China

Xuzhou Medical University Affiliated Hospital

Xuzhou, Jiangsu, China

China-Japan Union Hospital of Jilin University

Changchun, Jilin, China

Jilin University Second Hospital

Changchun, Jilin, China

Xi'an Jiaotong University Second Hospital

Xi'an, Shaanxi, China

Southwest Medical University Affiliated Hospital

Luzhou, Sichuan, China

Peking University Binhai Hospital

Tianjin, Tianjin Municipality, China

First Hospital of Peking University

Beijing, China

Heilongjiang provincial hospital

Harbin, China

Henan People's Hospital

Zhengzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03987308

Related Trials

A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

NCT073470801 location

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

NCT073216788 locations

Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes

NCT069421951 location

GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

NCT073146842 locations

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

NCT072440031 location